<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ZITHROMAX - azithromycin, unspecified form tablet, film coated </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>ZITHROMAX® (azithromycin tablets) and (azithromycin for oral suspension)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX<span class="Sup">®</span> (azithromycin) and other antibacterial drugs, ZITHROMAX (azithromycin) should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>ZITHROMAX (azithromycin tablets and azithromycin for oral suspension) contain the active ingredient azithromycin, an azalide, a subclass of macrolide antibiotics, for oral administration. Azithromycin has the chemical name (<span class="Italics">2R,3S,4R,5R,8R, 10R,11R,12S,13S,14R</span>)-13-[(2,6-dideoxy-3-<span class="Italics">C</span>-methyl-3-<span class="Italics">O</span>-methyl-α-<span class="Italics">L</span>-<span class="Italics">ribo</span>-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-<span class="Italics">D-xylo</span>-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring. Its molecular formula is C<span class="Sub">38</span>H<span class="Sub">72</span>N<span class="Sub">2</span>O<span class="Sub">12</span>, and its molecular weight is 749.00. Azithromycin has the following structural formula:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=931a3c19-23d3-4b65-a422-32bd98de5de4&amp;name=MM1.jpg"></p>
<p>Azithromycin, as the dihydrate, is a white crystalline powder with a molecular formula of C<span class="Sub">38</span>H<span class="Sub">72</span>N<span class="Sub">2</span>O<span class="Sub">12</span>•2H<span class="Sub">2</span>O and a molecular weight of 785.0.</p>
<p>ZITHROMAX is supplied for oral administration as film-coated, modified capsular shaped tablets containing azithromycin dihydrate equivalent to either 250 mg or 500 mg azithromycin and the following inactive ingredients: dibasic calcium phosphate anhydrous, pregelatinized starch, sodium croscarmellose, magnesium stearate, sodium lauryl sulfate, hypromellose, lactose, titanium dioxide, triacetin and D&amp;C Red #30 aluminum lake.</p>
<p>ZITHROMAX for oral suspension is supplied in bottles containing azithromycin dihydrate powder equivalent to 300 mg, 600 mg, 900 mg, or 1200 mg azithromycin per bottle and the following inactive ingredients: sucrose; sodium phosphate, tribasic, anhydrous; hydroxypropyl cellulose; xanthan gum; FD&amp;C Red #40; and spray dried artificial cherry, creme de vanilla and banana flavors. After constitution, each 5 mL of suspension contains 100 mg or 200 mg of azithromycin.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Following oral administration of a single 500 mg dose (two 250 mg tablets) to 36 fasted healthy male volunteers, the mean (SD) pharmacokinetic parameters were AUC<span class="Sub">0–72 </span>= 4.3 (1.2) µg∙h/mL; C<span class="Sub">max </span>= 0.5 (0.2) µg/mL; T<span class="Sub">max</span> = 2.2 (0.9) hours.</p>
<p>With a regimen of 500 mg (two 250 mg capsules<a href="#footnote-1">1</a>) on day 1, followed by 250 mg daily (one 250 mg capsule) on days 2 through 5, the pharmacokinetic parameters of azithromycin in plasma in healthy young adults (18–40 years of age) are portrayed in the chart below. C<span class="Sub">min</span> and C<span class="Sub">max</span> remained essentially unchanged from day 2 through day 5 of therapy.</p>
<table width="75%">
<col align="left" span="1" width="34%">
<col align="center" span="1" width="33%">
<col align="center" span="1" width="33%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Pharmacokinetic Parameters (Mean)</th>
<th align="center" colspan="1">Total n=12<br><span class="Underline">Day 1</span>
</th>
<th align="center" colspan="1"> <br><span class="Underline">Day 5</span>
</th>
</tr>
<tr>
<td align="left">C<span class="Sub">max</span> (µg/mL)</td>
<td align="center">0.41</td>
<td align="center">0.24</td>
</tr>
<tr>
<td align="left">T<span class="Sub">max</span> (h)</td>
<td align="center">2.5</td>
<td align="center">3.2</td>
</tr>
<tr>
<td align="left">AUC<span class="Sub">0–24</span> (µg∙h/mL)</td>
<td align="center">2.6</td>
<td align="center">2.1</td>
</tr>
<tr>
<td align="left">C<span class="Sub">min</span> (µg/mL)</td>
<td align="center">0.05</td>
<td align="center">0.05</td>
</tr>
<tr class="Last">
<td align="left">Urinary Excret. (% dose)</td>
<td align="center">4.5</td>
<td align="center">6.5</td>
</tr>
</tbody>
</table>
<p>In a two-way crossover study, 12 adult healthy volunteers (6 males, 6 females) received 1,500 mg of azithromycin administered in single daily doses over either 5 days (two 250 mg tablets on day 1, followed by one 250 mg tablet on days 2–5) or 3 days (500 mg per day for days 1–3). Due to limited serum samples on day 2 (3-day regimen) and days 2–4 (5-day regimen), the serum concentration-time profile of each subject was fit to a 3-compartment model and the AUC<span class="Sub">0–</span><span class="Sub">∞</span> for the fitted concentration profile was comparable between the 5-day and 3-day regimens.</p>
<table width="75%">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<tbody class="Headless">
<tr class="First">
<th colspan="1"></th>
<th colspan="2">3-Day Regimen</th>
<th colspan="2">5-Day Regimen</th>
</tr>
<tr>
<th colspan="1">Pharmacokinetic Parameter<br>[mean (SD)]</th>
<th colspan="1">Day 1</th>
<th colspan="1">Day 3</th>
<th colspan="1">Day 1</th>
<th colspan="1">Day 5</th>
</tr>
<tr>
<td>C<span class="Sub">max</span> (serum, µg/mL)</td>
<td>0.44 (0.22)</td>
<td>0.54 (0.25)</td>
<td>0.43 (0.20)</td>
<td>0.24 (0.06)</td>
</tr>
<tr>
<td>Serum AUC<span class="Sub">0–</span><span class="Sub">∞</span> (µg∙hr/mL)</td>
<td>17.4 (6.2)<a href="#footnote-2">*</a>
</td>
<td>14.9 (3.1)<a href="#footnote-1" class="Sup">1</a>
</td>
</tr>
<tr class="Last">
<td>Serum T<span class="Sub">1/2</span>
</td>
<td>71.8 hr</td>
<td>68.9 hr</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<p>Median azithromycin exposure (AUC<span class="Sub">0–288</span>) in mononuclear (MN) and polymorphonuclear (PMN) leukocytes following either the 5-day or 3-day regimen was more than a 1000-fold and 800-fold greater than in serum, respectively. Administration of the same total dose with either the 5-day or 3-day regimen may be expected to provide comparable concentrations of azithromycin within MN and PMN leukocytes.</p>
<p>Two azithromycin 250 mg tablets are bioequivalent to a single 500 mg tablet.</p>
<p><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a></p>
<p>
 
</p>
<p></p>
<p>The absolute bioavailability of azithromycin 250 mg capsules is 38%.</p>
<p>In a two-way crossover study in which 12 healthy subjects received a single 500 mg dose of azithromycin (two 250 mg tablets) with or without a high fat meal, food was shown to increase C<span class="Sub">max</span> by 23% but had no effect on AUC.</p>
<p>When azithromycin suspension was administered with food to 28 adult healthy male subjects, C<span class="Sub">max</span> increased by 56% and AUC was unchanged.</p>
<p>The AUC of azithromycin was unaffected by co-administration of an antacid containing aluminum and magnesium hydroxide with azithromycin capsules; however, the C<span class="Sub">max</span> was reduced by 24%. Administration of cimetidine (800 mg) two hours prior to azithromycin had no effect on azithromycin absorption.</p>
<p>
 
</p>
<p></p>
<p>The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 µg/mL to 7% at 2 µg/mL.</p>
<p>Following oral administration, azithromycin is widely distributed throughout the body with an apparent steady-state volume of distribution of 31.1 L/kg. Greater azithromycin concentrations in tissues than in plasma or serum were observed. High tissue concentrations should not be interpreted to be quantitatively related to clinical efficacy. The antimicrobial activity of azithromycin is pH related and appears to be reduced with decreasing pH. However, the extensive distribution of drug to tissues may be relevant to clinical activity.</p>
<p>Selected tissue (or fluid) concentration and tissue (or fluid) to plasma/serum concentration ratios are shown in the following table:</p>
<table width="100%">
<caption><span>AZITHROMYCIN CONCENTRATIONS FOLLOWING A 500 mg DOSE (TWO 250 mg CAPSULES) IN ADULTS<a href="#footnote-1">*</a></span></caption>
<col align="left" span="1" width="20%">
<col align="center" span="1" width="20%">
<col align="center" span="1" width="20%">
<col align="center" span="1" width="20%">
<col align="center" span="1" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">TISSUE OR FLUID</th>
<th align="center" colspan="1"> TIME AFTER DOSE (h)</th>
<th align="center" colspan="1">TISSUE OR FLUID CONCENTRATION<br>(µg/g or µg/mL)</th>
<th align="center" colspan="1">CORRESPONDING<br>PLASMA OR SERUM<br>LEVEL (µg/mL)</th>
<th align="center" colspan="1">
<span class="Underline">TISSUE (FLUID)</span><br>PLASMA (SERUM)<br>RATIO</th>
</tr>
<tr>
<td align="left">SKIN</td>
<td align="center">72–96</td>
<td align="center">0.4</td>
<td align="center">0.012</td>
<td align="center">35</td>
</tr>
<tr>
<td align="left">LUNG</td>
<td align="center">72–96</td>
<td align="center">4.0</td>
<td align="center">0.012</td>
<td align="center">&gt;100</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">SPUTUM</span><a href="#footnote-2">†</a>
</td>
<td align="center">2–4</td>
<td align="center">1.0</td>
<td align="center">0.64</td>
<td align="center">      2</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">SPUTUM</span><a href="#footnote-3">‡</a>
</td>
<td align="center">10–12</td>
<td align="center">2.9</td>
<td align="center">0.1</td>
<td align="center">    30</td>
</tr>
<tr>
<td align="left">TONSIL<a href="#footnote-4">§</a>
</td>
<td align="center">9–18</td>
<td align="center">4.5</td>
<td align="center">0.03</td>
<td align="center">&gt;100</td>
</tr>
<tr>
<td align="left">TONSIL<a href="#footnote-6" class="Sup">6</a>
</td>
<td align="center">180</td>
<td align="center">0.9</td>
<td align="center">0.006</td>
<td align="center">&gt;100</td>
</tr>
<tr class="Last">
<td align="left">CERVIX<a href="#footnote-5">¶</a>
</td>
<td align="center">19</td>
<td align="center">2.8</td>
<td align="center">0.04</td>
<td align="center">    70</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a></p>
<p><a name="footnote-reference-4" href="#footnote-4" class="Sup">4</a></p>
<p><a name="footnote-reference-5" href="#footnote-5" class="Sup">5</a></p>
<p><a name="footnote-reference-6" href="#footnote-6" class="Sup">6</a></p>
<p><a name="footnote-reference-7" href="#footnote-7" class="Sup">7</a></p>
<p>The extensive tissue distribution was confirmed by examination of additional tissues and fluids (bone, ejaculum, prostate, ovary, uterus, salpinx, stomach, liver, and gallbladder). As there are no data from adequate and well-controlled studies of azithromycin treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in these additional body sites, the clinical importance of these tissue concentration data is unknown.</p>
<p>Following a regimen of 500 mg on the first day and 250 mg daily for 4 days, only very low concentrations were noted in cerebrospinal fluid (less than 0.01 µg/mL) in the presence of non-inflamed meninges.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies to assess the metabolism of azithromycin have not been performed.</p>
<p>
 
</p>
<p></p>
<p>Plasma concentrations of azithromycin following single 500 mg oral and i.v. doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours. The prolonged terminal half-life is thought to be due to extensive uptake and subsequent release of drug from tissues.</p>
<p>Biliary excretion of azithromycin, predominantly as unchanged drug, is a major route of elimination. Over the course of a week, approximately 6% of the administered dose appears as unchanged drug in urine.</p>
<p>
 
</p>
<p></p>
<p>Azithromycin pharmacokinetics were investigated in 42 adults (21 to 85 years of age) with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Following the oral administration of a single 1,000 mg dose of azithromycin, mean C<span class="Sub">max</span> and AUC<span class="Sub">0–120 </span>increased by 5.1% and 4.2%, respectively in subjects with mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR 10 to 80 mL/min) compared to subjects with normal renal function (GFR &gt;80 mL/min). The mean C<span class="Sub">max</span> and AUC<span class="Sub">0–120 </span>increased 61% and 35%, respectively in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;10 mL/min) compared to subjects with normal renal function (GFR &gt;80 mL/min). (See <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a>.</span>)</p>
<p>
 
</p>
<p></p>
<p>The pharmacokinetics of azithromycin in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been established.</p>
<p>
 
</p>
<p></p>
<p>There are no significant differences in the disposition of azithromycin between male and female subjects. No dosage adjustment is recommended based on gender.</p>
<p>
 
</p>
<p></p>
<p>When studied in healthy elderly subjects aged 65 to 85 years, the pharmacokinetic parameters of azithromycin in elderly men were similar to those in young adults; however, in elderly women, although higher peak concentrations (increased by 30 to 50%) were observed, no significant accumulation occurred.</p>
<p>
 
</p>
<p></p>
<p>In two clinical studies, azithromycin for oral suspension was dosed at 10 mg/kg on day 1, followed by 5 mg/kg on days 2 through 5 to two groups of pediatric patients (aged 1–5 years and 5–15 years, respectively). The mean pharmacokinetic parameters on day 5 were C<span class="Sub">max</span>=0.216 µg/mL, T<span class="Sub">max</span>=1.9 hours, and AUC<span class="Sub">0–24</span>=1.822 µg∙hr/mL for the 1- to 5-year-old group and were C<span class="Sub">max</span>=0.383 µg/mL, T<span class="Sub">max</span>=2.4 hours, and AUC<span class="Sub">0–24</span>=3.109 µg∙hr/mL for the 5- to 15-year-old group.</p>
<p>Two clinical studies were conducted in 68 pediatric patients aged 3–16 years to determine the pharmacokinetics and safety of azithromycin for oral suspension. Azithromycin was administered following a low-fat breakfast.</p>
<p>The first study consisted of 35 pediatric patients treated with 20 mg/kg/day (maximum daily dose 500 mg) for 3 days of whom 34 patients were evaluated for pharmacokinetics. </p>
<p>In the second study, 33 pediatric patients received doses of 12 mg/kg/day (maximum daily dose 500 mg) for 5 days of whom 31 patients were evaluated for pharmacokinetics.</p>
<p>In both studies, azithromycin concentrations were determined over a 24 hour period following the last daily dose. Patients weighing above 25.0 kg in the 3-day study or 41.7 kg in the 5-day study received the maximum adult daily dose of 500 mg. Eleven patients (weighing 25.0 kg or less) in the first study and 17 patients (weighing 41.7 kg or less) in the second study received a total dose of 60 mg/kg. The following table shows pharmacokinetic data in the subset of pediatric patients who received a total dose of 60 mg/kg.</p>
<table width="75%">
<col align="left" span="1" width="40%">
<col align="left" span="1" width="30%">
<col align="left" span="1" width="30%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Pharmacokinetic Parameter<br>[mean (SD)]</th>
<th align="left" colspan="1">3-Day Regimen<br>(20 mg/kg × 3 days)</th>
<th align="left" colspan="1">5-Day Regimen<br>(12 mg/kg × 5 days)</th>
</tr>
<tr>
<td align="left">n</td>
<td align="left">11</td>
<td align="left">17</td>
</tr>
<tr>
<td align="left">C<span class="Sub">max </span>(µg/mL)</td>
<td align="left">1.1 (0.4)</td>
<td align="left">0.5 (0.4)</td>
</tr>
<tr>
<td align="left">T<span class="Sub">max </span>(hr)</td>
<td align="left">2.7 (1.9) </td>
<td align="left">2.2 (0.8)</td>
</tr>
<tr class="Last">
<td align="left">AUC<span class="Sub">0–24</span>(µg∙hr/mL)</td>
<td align="left">7.9 (2.9)</td>
<td align="left">3.9 (1.9)</td>
</tr>
</tbody>
</table>
<p>The similarity of the overall exposure (AUC<span class="Sub">0–∞</span>) between the 3-day and 5-day regimens in pediatric patients is unknown.</p>
<p>Single dose pharmacokinetics in pediatric patients given doses of 30 mg/kg have not been studied. (See <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a>.</span>)</p>
<p>
 
</p>
<p></p>
<p>Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered. The effects of co-administration of azithromycin on the pharmacokinetics of other drugs are shown in Table 1 and the effect of other drugs on the pharmacokinetics of azithromycin are shown in Table 2. </p>
<p>Co-administration of azithromycin at therapeutic doses had a modest effect on the pharmacokinetics of the drugs listed in Table 1. No dosage adjustment of drugs listed in Table 1 is recommended when co-administered with azithromycin.</p>
<p>Co-administration of azithromycin with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. Nelfinavir significantly increased the C<span class="Sub">max</span> and AUC of azithromycin. No dosage adjustment of azithromycin is recommended when administered with drugs listed in Table 2. (See <span class="Bold"><a href="#Drug_Interactions">PRECAUTIONS - Drug Interactions</a>.</span>)</p>
<table width="100%">
<caption><span>Table 1. Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Azithromycin </span></caption>
<col align="left" span="1" valign="top" width="10%">
<col align="left" span="1" valign="top" width="18%">
<col align="left" span="1" valign="top" width="18%">
<col align="center" span="1" valign="top" width="6%">
<col align="center" span="1" valign="top" width="24%">
<col align="center" span="1" valign="top" width="24%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Co-administered  Drug</th>
<th align="left" colspan="1">Dose of  Co-administered Drug</th>
<th align="left" colspan="1">Dose of Azithromycin</th>
<th align="center" colspan="1">n</th>
<th align="center" colspan="2">Ratio  (with/without azithromycin) of Co-administered Drug Pharmacokinetic  Parameters (90% CI); No Effect = 1.00</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1">Mean C<span class="Sub">max</span>
</th>
<th align="center" colspan="1">Mean AUC</th>
</tr>
<tr>
<td align="left">												Atorvastatin 											</td>
<td align="left">10 mg/day × 8 days</td>
<td align="left">500 mg/day PO on days 6–8</td>
<td align="center">12</td>
<td align="center">0.83<br>(0.63 to 1.08)</td>
<td align="center">1.01<br>(0.81 to 1.25)</td>
</tr>
<tr>
<td align="left">												Carbamazepine 											</td>
<td align="left">200 mg/day × 2 days, then 200 mg BID × 18 days</td>
<td align="left">500 mg/day PO for days 16–18</td>
<td align="center">7</td>
<td align="center">0.97<br> (0.88 to 1.06)</td>
<td align="center">0.96<br> (0.88 to 1.06)</td>
</tr>
<tr>
<td align="left">												Cetirizine 											</td>
<td align="left">20 mg/day × 11 days</td>
<td align="left">500 mg PO on day 7, then 250 mg/day on days 8–11</td>
<td align="center">14</td>
<td align="center">1.03<br> (0.93 to 1.14)</td>
<td align="center">1.02<br> (0.92 to 1.13)</td>
</tr>
<tr>
<td align="left">												Didanosine 											</td>
<td align="left">200 mg PO BID × 21 days</td>
<td align="left">1,200 mg/day PO on days 8–21</td>
<td align="center">6</td>
<td align="center">1.44<br> (0.85 to 2.43)</td>
<td align="center">1.14<br> (0.83 to 1.57)</td>
</tr>
<tr>
<td align="left">												Efavirenz 											</td>
<td align="left">400 mg/day × 7 days </td>
<td align="left">600 mg PO on day 7</td>
<td align="center">14</td>
<td align="center">1.04<a href="#footnote-1">*</a>
</td>
<td align="center">0.95<a href="#footnote-8" class="Sup">8</a>
</td>
</tr>
<tr>
<td align="left">												Fluconazole 											</td>
<td align="left">200 mg PO single dose </td>
<td align="left">1,200 mg PO single dose</td>
<td align="center">18</td>
<td align="center">1.04<br> (0.98 to 1.11)</td>
<td align="center">1.01<br> (0.97 to 1.05)</td>
</tr>
<tr>
<td align="left">												Indinavir 											</td>
<td align="left">800 mg TID × 5 days</td>
<td align="left">1,200 mg PO on day 5</td>
<td align="center">18</td>
<td align="center">0.96<br> (0.86 to 1.08)</td>
<td align="center">0.90<br> (0.81 to 1.00)</td>
</tr>
<tr>
<td align="left">												Midazolam 											</td>
<td align="left">15 mg PO on day 3</td>
<td align="left">500 mg/day PO × 3 days</td>
<td align="center">12</td>
<td align="center">1.27<br> (0.89 to 1.81)</td>
<td align="center">1.26<br> (1.01 to 1.56)</td>
</tr>
<tr>
<td align="left">												Nelfinavir 											</td>
<td align="left">750 mg TID × 11 days</td>
<td align="left">1,200 mg PO on day 9</td>
<td align="center">14</td>
<td align="center">0.90<br> (0.81 to 1.01)</td>
<td align="center">0.85<br> (0.78 to 0.93)</td>
</tr>
<tr>
<td align="left">												Rifabutin 											</td>
<td align="left">300 mg/day × 10 days</td>
<td align="left">500 mg PO on day 1, then 250 mg/day on days 2–10</td>
<td align="center">6</td>
<td align="center">See footnote below</td>
<td align="center">NA</td>
</tr>
<tr>
<td align="left">												Sildenafil 											</td>
<td align="left">100 mg on days 1 and 4</td>
<td align="left">500 mg/day PO × 3 days</td>
<td align="center">12</td>
<td align="center">1.16<br> (0.86 to 1.57)</td>
<td align="center">0.92<br> (0.75 to 1.12)</td>
</tr>
<tr>
<td align="left">												Theophylline 											</td>
<td align="left">4 mg/kg IV on days 1, 11, 25</td>
<td align="left">500 mg PO on day 7, 250 mg/day on days 8–11</td>
<td align="center">10</td>
<td align="center">1.19<br> (1.02 to 1.40)</td>
<td align="center">1.02<br> (0.86 to 1.22)</td>
</tr>
<tr>
<td align="left">												Theophylline 											</td>
<td align="left">300 mg PO BID ×<br> 15 days</td>
<td align="left">500 mg PO on day 6, then 250 mg/day on days 7–10</td>
<td align="center">8</td>
<td align="center">1.09<br> (0.92 to 1.29)</td>
<td align="center">1.08<br> (0.89 to 1.31)</td>
</tr>
<tr>
<td align="left">												Triazolam 											</td>
<td align="left">0.125 mg on day 2</td>
<td align="left">500 mg PO on day 1, then 250 mg/day on day 2</td>
<td align="center">12</td>
<td align="center">1.06<a href="#footnote-8" class="Sup">8</a>
</td>
<td align="center">1.02<a href="#footnote-8" class="Sup">8</a>
</td>
</tr>
<tr>
<td align="left">												Trimethoprim/Sulfamethoxazole 											</td>
<td align="left">160 mg/800 mg/day PO × 7 days</td>
<td align="left">1,200 mg PO on day 7</td>
<td align="center">12</td>
<td align="center">0.85<br> (0.75 to 0.97)/<br> 0.90<br> (0.78 to 1.03)</td>
<td align="center">0.87<br> (0.80 to 0.95/<br> 0.96<br> (0.88 to 1.03)</td>
</tr>
<tr>
<td align="left">Zidovudine</td>
<td align="left">500 mg/day PO × 21 days</td>
<td align="left">600 mg/day PO × 14 days</td>
<td align="center">5</td>
<td align="center">1.12<br> (0.42 to 3.02)</td>
<td align="center">0.94<br> (0.52 to 1.70)</td>
</tr>
<tr class="Last">
<td align="left">												Zidovudine 											</td>
<td align="left">500 mg/day PO × 21 days</td>
<td align="left">1,200 mg/day PO × 14 days</td>
<td align="center">4</td>
<td align="center">1.31<br> (0.43 to 3.97)</td>
<td align="center">1.30<br> (0.69 to 2.43)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-8" href="#footnote-8" class="Sup">8</a></p>
<table width="100%">
<caption><span>Table 2. Drug Interactions: Pharmacokinetic Parameters for Azithromycin in the Presence of Co-administered Drugs (See <a href="#Drug_Interactions">PRECAUTIONS - Drug Interactions</a>.)</span></caption>
<col align="left" span="1" valign="top" width="14%">
<col align="left" span="1" valign="top" width="18%">
<col align="left" span="1" valign="top" width="18%">
<col align="center" span="1" valign="top" width="6%">
<col align="center" span="1" valign="top" width="22%">
<col align="center" span="1" valign="top" width="22%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Co-administered  Drug</th>
<th align="left" colspan="1">Dose of  Co-administered Drug</th>
<th align="left" colspan="1">Dose of  Azithromycin</th>
<th align="center" colspan="1">n</th>
<th align="center" colspan="2">Ratio (with/without co-administered drug) of Azithromycin Pharmacokinetic Parameters (90% CI); No Effect = 1.00</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1">Mean C<span class="Sub">max</span>
</th>
<th align="center" colspan="1">Mean AUC</th>
</tr>
<tr>
<td align="left">												Efavirenz 											</td>
<td align="left">400 mg/day × 7 days </td>
<td align="left">600 mg PO on day 7</td>
<td align="center">14</td>
<td align="center">1.22<br>(1.04 to 1.42)</td>
<td align="center">0.92<a href="#footnote-2">*</a>
</td>
</tr>
<tr>
<td align="left">												Fluconazole 											</td>
<td align="left">200 mg PO single dose</td>
<td align="left">1,200 mg PO single dose</td>
<td align="center">18</td>
<td align="center">0.82<br>(0.66 to 1.02)</td>
<td align="center">1.07<br>(0.94 to 1.22)</td>
</tr>
<tr>
<td align="left">												Nelfinavir 											</td>
<td align="left">750 mg TID × 11 days</td>
<td align="left">1,200 mg PO on day 9</td>
<td align="center">14</td>
<td align="center">2.36<br>(1.77 to 3.15)</td>
<td align="center">2.12<br>(1.80 to 2.50)</td>
</tr>
<tr class="Last">
<td align="left">												Rifabutin 											</td>
<td align="left">300 mg/day × 10 days</td>
<td align="left">500 mg PO on day 1, then 250 mg/day on days 2–10</td>
<td align="center">6</td>
<td align="center">See footnote below</td>
<td align="center">NA</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-9" href="#footnote-9" class="Sup">9</a></p>
<p>
 
</p>
<p></p>
<p>Azithromycin acts by binding to the 50S ribosomal subunit of susceptible microorganisms and, thus, interfering with microbial protein synthesis. Nucleic acid synthesis is not affected.</p>
<p>Azithromycin concentrates in phagocytes and fibroblasts as demonstrated by <span class="Italics">in vitro</span> incubation techniques. Using such methodology, the ratio of intracellular to extracellular concentration was &gt;30 after one hour incubation. <span class="Italics">In vivo</span> studies suggest that concentration in phagocytes may contribute to drug distribution to inflamed tissues.</p>
<p>Azithromycin has been shown to be active against most isolates of the following microorganisms, both <span class="Italics">in vitro</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the <span class="Bold"><a href="#INDICATIONS">INDICATIONS AND USAGE</a></span> section.</p>
<p><span class="Bold">Aerobic and facultative gram-positive microorganisms</span><br>    <span class="Italics">Staphylococcus aureus</span><br>    <span class="Italics">Streptococcus agalactiae</span><br>    <span class="Italics">Streptococcus pneumoniae</span><br>    <span class="Italics">Streptococcus pyogenes</span></p>
<p>NOTE: Azithromycin demonstrates cross-resistance with erythromycin-resistant gram-positive <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Enterococcus faecalis</span> and methicillin-resistant staphylococci are resistant to azithromycin.</p>
<p><span class="Bold">Aerobic and facultative gram-negative microorganisms</span><br>    <span class="Italics">Haemophilus ducreyi</span><br>    <span class="Italics">Haemophilus influenzae</span><br>    <span class="Italics">Moraxella catarrhalis</span><br>    <span class="Italics">Neisseria gonorrhoeae</span></p>
<p><span class="Bold">"Other" microorganisms</span><br>    <span class="Italics">Chlamydia pneumoniae</span><br>    <span class="Italics">Chlamydia trachomatis</span><br>    <span class="Italics">Mycoplasma pneumoniae</span></p>
<p>Beta-lactamase production should have no effect on azithromycin activity.</p>
<p>The following <span class="Italics">in vitro </span>data are available, <span>but their clinical significance is unknown</span>. 								</p>
<p>At least 90% of the following microorganisms exhibit an <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoints for azithromycin. However, the safety and effectiveness of azithromycin in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these microorganisms have not been established in adequate and well-controlled trials.</p>
<p><span class="Bold">Aerobic and facultative gram-positive microorganisms</span><br>    Streptococci (Groups C, F, G)<br>    Viridans group streptococci</p>
<p><span class="Bold">Aerobic and facultative gram-negative microorganisms</span><br>    <span class="Italics">Bordetella <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span></span><br>    <span class="Italics">Legionella pneumophila</span></p>
<p><span class="Bold">Anaerobic microorganisms</span><br>    <span class="Italics">Peptostreptococcus</span> species<br>    <span class="Italics">Prevotella bivia</span></p>
<p><span class="Bold">"Other" microorganisms</span><br>    <span class="Italics">Ureaplasma urealyticum</span></p>
<p>
 
</p>
<p></p>
<p>When available, the results of <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in resident hospitals should be provided to the physician as periodic reports which describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports may differ from susceptibility data obtained from outpatient use, but could aid the physician in selecting the most effective antimicrobial.</p>
<p>
 
</p>
<p></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method<span class="Sup">1,3</span> (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of azithromycin powder. The MIC values should be interpreted according to criteria provided in Table 3.</p>
<p>
 
</p>
<p></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure<span class="Sup">2,3</span> requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 15-µg azithromycin to test the susceptibility of microorganisms to azithromycin. The disk diffusion interpretive criteria are provided in Table 3.</p>
<table width="100%">
<caption><span>Table 3.  Susceptibility Interpretive Criteria for Azithromycin</span></caption>
<col align="left" span="1" width="28%">
<col align="center" span="1" width="12%">
<col align="center" span="1" width="12%">
<col align="center" span="1" width="12%">
<col align="center" span="1" width="12%">
<col align="center" span="1" width="12%">
<col align="center" span="1" width="12%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="7">Susceptibility Test Result Interpretive Criteria</th></tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="3"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (µg/mL)</th>
<th align="center" colspan="3">Disk Diffusion<br>(zone diameters in mm)</th>
</tr>
<tr>
<th align="left" colspan="1">Pathogen</th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1"></th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="1">S</th>
<th align="center" colspan="1">I</th>
<th align="center" colspan="1">R<a href="#footnote-1">*</a>
</th>
<th align="center" colspan="1">S</th>
<th align="center" colspan="1">I</th>
<th align="center" colspan="1">R<a href="#footnote-10" class="Sup">10</a>
</th>
</tr>
<tr>
<td align="left">
<span class="Italics">Haemophilus</span> spp.</td>
<td align="center">≤ 4</td>
<td align="center">--</td>
<td align="center">--</td>
<td align="center">≥ 12</td>
<td align="center">--</td>
<td align="center">--</td>
</tr>
<tr>
<td align="left"><span class="Italics">Staphylococcus aureus</span></td>
<td align="center">≤ 2</td>
<td align="center">4</td>
<td align="center">≥ 8</td>
<td align="center">≥ 18</td>
<td align="center">14–17</td>
<td align="center">≤ 13</td>
</tr>
<tr class="Last">
<td align="left">Streptococci including <span class="Italics">S. pneumoniae</span><a href="#footnote-2">†</a>
</td>
<td align="center">≤ 0.5</td>
<td align="center">1</td>
<td align="center">≥ 2</td>
<td align="center">≥ 18</td>
<td align="center">14–17</td>
<td align="center">≤ 13</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-10" href="#footnote-10" class="Sup">10</a></p>
<p><a name="footnote-reference-11" href="#footnote-11" class="Sup">11</a></p>
<p>No interpretive criteria have been established for testing <span class="Italics">Neisseria gonorrhoeae.</span> This species is not usually tested.</p>
<p>A report of "susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable. A report of "intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound reaches the concentrations usually achievable; other therapy should be selected.</p>
<p>
 
</p>
<p></p>
<p>Standardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the test procedures. Standard azithromycin powder should provide the following range of values noted in Table 4. Quality control microorganisms are specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of organisms with intrinsic biological properties. QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are very stable <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> which will give a standard and repeatable susceptibility pattern. The specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used for microbiological quality control are not clinically significant.</p>
<table width="75%">
<caption><span>Table 4.  Acceptable Quality Control Ranges for Azithromycin</span></caption>
<col align="left" span="1" width="33%">
<col align="center" span="1" width="34%">
<col align="center" span="1" width="33%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (µg/mL)</th>
<th align="center" colspan="1">Disk Diffusion<br>(zone diameters in mm) 			</th>
</tr>
<tr>
<td align="left">
<span class="Italics">Haemophilus influenzae</span><br>  ATCC 49247</td>
<td align="center">1.0–4.0</td>
<td align="center">13–21</td>
</tr>
<tr>
<td align="left">
<span class="Italics">Staphylococcus aureus</span><br>  ATCC 29213</td>
<td align="center">0.5–2.0</td>
<td align="center"></td>
</tr>
<tr>
<td align="left">
<span class="Italics">Staphylococcus aureus</span><br>  ATCC 25923</td>
<td align="center"></td>
<td align="center">21–26</td>
</tr>
<tr class="Last">
<td align="left">
<span class="Italics">Streptococcus pneumoniae</span><br>  ATCC 49619</td>
<td align="center">0.06–0.25</td>
<td align="center">19–25</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>Total AUC for the entire 3-day and 5-day regimens</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>Azithromycin 250 mg tablets are bioequivalent to 250 mg capsules in the fasted state.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd>Azithromycin tissue concentrations were originally determined using 250 mg capsules.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">4</a></dt>
<dd>Sample was obtained 2–4 hours after the first dose.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">5</a></dt>
<dd>Sample was obtained 10–12 hours after the first dose.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">6</a></dt>
<dd>Dosing regimen of two doses of 250 mg each, separated by 12 hours.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">7</a></dt>
<dd>Sample was obtained 19 hours after a single 500 mg dose.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">8</a></dt>
<dd>- 90% Confidence interval not reported</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">9</a></dt>
<dd>- 90% Confidence interval not reported</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">10</a></dt>
<dd>The current absence of data on resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> precludes defining any category other than "susceptible." If <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> yield MIC results other than susceptible, they should be submitted to a reference laboratory for further testing.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">11</a></dt>
<dd>Susceptibility of streptococci including </dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>ZITHROMAX (azithromycin) is indicated for the treatment of patients with mild to moderate <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>: see <span class="Bold"><a href="#WARNINGS">WARNINGS</a></span>) caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated microorganisms in the specific conditions listed below. <span class="Underline">As recommended dosages, durations of therapy and applicable patient populations vary among these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, please see <span><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span> for specific dosing recommendations</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Acute bacterial exacerbations of <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span></span> due to <span class="Italics">Haemophilus influenzae, Moraxella catarrhalis</span> or <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p><span class="Bold">Acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span></span> due to <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis </span>or <span class="Italics">Streptococcus pneumoniae</span>.</p>
<p>Community<span class="Bold">-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span></span> due to <span class="Italics">Chlamydia pneumoniae</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Mycoplasma pneumoniae</span> or <span class="Italics">Streptococcus pneumoniae</span> in patients appropriate for oral therapy.</p>
<p><span class="Bold">NOTE: Azithromycin should not be used in patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following:</span></p>
<p> </p>
<p><span class="Bold">patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>,</span></p>
<p> </p>
<p><span class="Bold">patients with nosocomially acquired <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>,</span></p>
<p> </p>
<p><span class="Bold">patients with known or suspected <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>,</span></p>
<p> </p>
<p><span class="Bold">patients requiring hospitalization,</span></p>
<p> </p>
<p><span class="Bold">elderly or debilitated patients, or</span></p>
<p> </p>
<p><span class="Bold">patients with significant underlying health problems that may compromise their ability to respond to their illness (including <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> or functional <span class="product-label-link" type="condition" conceptid="45768671" conceptname="Asplenia">asplenia</span>).</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span></span> caused by <span class="Italics">Streptococcus pyogenes</span> as an alternative to first-line therapy in individuals who cannot use first-line therapy.</p>
<p> NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of </p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. ZITHROMAX is often effective in the eradication of susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of </p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p> from the nasopharynx. Because some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are resistant to ZITHROMAX, susceptibility tests should be performed when patients are treated with ZITHROMAX. Data establishing efficacy of azithromycin in subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available.</p>
<p><span class="Bold">Uncomplicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></span> due to <span class="Italics">Staphylococcus aureus</span>, <span class="Italics">Streptococcus pyogenes</span>, or <span class="Italics">Streptococcus agalactiae</span>. <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">Abscesses</span> usually require surgical drainage.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">Urethritis</span> and <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span></span> due to<span class="Italics"> Chlamydia trachomatis</span> or <span class="Italics">Neisseria gonorrhoeae</span>.</p>
<p><span class="Bold">Genital <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease</span> in men due to <span class="Italics">Haemophilus ducreyi</span> (<span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span>). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of <span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span> in women has not been established.</p>
<p>ZITHROMAX, at the recommended dose, should not be relied upon to treat <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> may mask or delay the symptoms of incubating <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span>. All patients with sexually-transmitted <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> or <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span> should have a serologic test for <span class="product-label-link" type="condition" conceptid="436033" conceptname="Syphilis">syphilis</span> and appropriate cultures for <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">gonorrhea</span> performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confirmed.</p>
<p>Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with ZITHROMAX may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZITHROMAX (azithromycin) and other antibacterial drugs, ZITHROMAX (azithromycin) should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p>
 
</p>
<p></p>
<p>(See <span class="Bold"><a href="#P_pediatric">PRECAUTIONS—Pediatric Use</a></span> and <span class="Bold"><a href="#CS_pediatric">CLINICAL STUDIES IN PEDIATRIC PATIENTS</a></span>.)</p>
<p><span class="Bold">Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span></span> caused by <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Moraxella catarrhalis</span> or <span class="Italics">Streptococcus pneumoniae</span>. (For specific dosage recommendation, see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p><span class="Bold">Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> </span>due to <span class="Italics">Chlamydia pneumoniae, Haemophilus influenzae,</span><span class="Italics"> Mycoplasma pneumoniae </span>or <span class="Italics">Streptococcus pneumoniae </span>in patients appropriate for oral therapy. (For specific dosage recommendation, see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p><span class="Bold">NOTE: Azithromycin should not be used in pediatric patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following:</span></p>
<p> </p>
<p><span class="Bold">patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>,</span></p>
<p> </p>
<p><span class="Bold">patients with nosocomially acquired <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>,</span></p>
<p> </p>
<p><span class="Bold">patients with known or suspected <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>,</span></p>
<p> </p>
<p><span class="Bold">patients requiring hospitalization, or</span></p>
<p> </p>
<p><span class="Bold">patients with significant underlying health problems that may compromise their ability to respond to their illness (including <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> or functional <span class="product-label-link" type="condition" conceptid="45768671" conceptname="Asplenia">asplenia</span>).</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span></span> caused by <span class="Italics">Streptococcus pyogenes</span> as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p> NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of </p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the prophylaxis of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span>. ZITHROMAX is often effective in the eradication of susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of </p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p> from the nasopharynx. Because some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are resistant to ZITHROMAX, susceptibility tests should be performed when patients are treated with ZITHROMAX. Data establishing efficacy of azithromycin in subsequent prevention of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> are not available.</p>
<p>Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with ZITHROMAX may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>ZITHROMAX is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Zithromax is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>/hepatic dysfunction  associated with prior use of azithromycin.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p>
 
</p>
<p></p>
<p>Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and dermatologic reactions including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens Johnson Syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported rarely in patients on azithromycin therapy. Although rare, fatalities have been reported. (See <span class="Bold"><a href="#CONTRAINDICATIONS">CONTRAINDICATIONS</a></span>.) Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms <span class="Bold">recurred soon thereafter in some patients without further azithromycin exposure</span>. These patients required <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is unknown at present.</p>
<p>If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that reappearance of the allergic symptoms may occur when symptomatic therapy is discontinued.</p>
<p>
 
</p>
<p></p>
<p>Abnormal liver function, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> have been reported, some of which have resulted in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Discontinue azithromycin immediately if signs and symptoms of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> occur.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">In the treatment of <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, azithromycin has only been shown to be safe and effective in the treatment of community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to <span class="Italics">Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae </span>or <span class="Italics">Streptococcus pneumoniae</span> in patients appropriate for oral therapy. Azithromycin should not be used in patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>, patients with nosocomially acquired <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, patients with known or suspected <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> or functional <span class="product-label-link" type="condition" conceptid="45768671" conceptname="Asplenia">asplenia</span>).</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including ZITHROMAX, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of  <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p>Because azithromycin is principally eliminated via the liver, caution should be exercised when azithromycin is administered to patients with impaired hepatic function. Due to the limited data in subjects with GFR &lt;10 mL/min, caution should be exercised when prescribing azithromycin in these patients. (See <span class="Bold"><a href="#renal">CLINICAL PHARMACOLOGY - Special Populations - <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a></span>.) </p>
<p>Prolonged cardiac repolarization and QT interval, imparting a risk of developing <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span> and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span></span>, have been seen in treatment with other macrolides. A similar effect with azithromycin cannot be completely ruled out in patients at increased risk for prolonged cardiac repolarization.</p>
<p>Exacerbation of symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> and new onset of <span class="product-label-link" type="condition" conceptid="4237155" conceptname="Eaton-Lambert syndrome">myasthenic syndrome</span> have been reported in patients receiving azithromycin therapy.</p>
<p>Prescribing ZITHROMAX (azithromycin) in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
<p>
 
</p>
<p></p>
<p>ZITHROMAX tablets and oral suspension can be taken with or without food.</p>
<p>Patients should also be cautioned not to take aluminum- and magnesium-containing antacids and azithromycin simultaneously.</p>
<p>The patient should be directed to discontinue azithromycin immediately and contact a physician if any signs of an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occur.</p>
<p>Patients should be counseled that antibacterial drugs including ZITHROMAX (azithromycin) should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When ZITHROMAX (azithromycin) is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of the therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by ZITHROMAX (azithromycin) or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic.  If this occurs, patients should contact their physician as soon as possible.</p>
<p>
 
</p>
<p></p>
<p>Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. (See <span class="Bold"><a href="#ADVERSE">ADVERSE REACTIONS</a></span>.)</p>
<p>Although, in a study of 22 healthy men, a 5-day course of azithromycin did not affect the <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time from a subsequently administered dose of warfarin, spontaneous post-marketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly.</p>
<p>Drug interaction studies were performed with azithromycin and other drugs likely to be co-administered. (See <span class="Bold"><a href="#C_drug">CLINICAL PHARMACOLOGY-Drug-Drug Interactions</a></span>.)  When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.  Co-administration with efavirenz, or fluconazole had a modest effect on the pharmacokinetics of azithromycin.  No dosage adjustment of either drug is recommended when azithromycin is coadministered with any of the above agents.</p>
<p>Interactions with the drugs listed below have not been reported in clinical trials with azithromycin; however, no specific drug interaction studies have been performed to evaluate potential drug-drug interaction. Nonetheless, they have been observed with macrolide products. Until further data are developed regarding drug interactions when azithromycin and these drugs are used concomitantly, careful monitoring of patients is advised:</p>
<p> Digoxin–elevated digoxin concentrations. Ergotamine or dihydroergotamine–acute ergot toxicity characterized by severe peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>. Terfenadine, cyclosporine, hexobarbital and phenytoin concentrations.</p>
<p>
 
</p>
<p></p>
<p>There are no reported laboratory test interactions.</p>
<p>
 
</p>
<p></p>
<p>Long-term studies in animals have not been performed to evaluate carcinogenic potential.  Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay.  No evidence of impaired fertility due to azithromycin was found.</p>
<p>
 
</p>
<p></p>
<p>Reproduction studies have been performed in rats and mice at doses up to moderately maternally toxic dose concentrations (i.e., 200 mg/kg/day). These doses, based on a mg/m<span class="Sup">2</span> basis, are estimated to be 4 and 2 times, respectively, the human daily dose of 500 mg. In the animal studies, no evidence of harm to the fetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.</p>
<p>
 
</p>
<p></p>
<p>It is not known whether azithromycin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when azithromycin is administered to a nursing woman.</p>
<p>
 
</p>
<p></p>
<p>(See <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a>, <a href="#INDICATIONS">INDICATIONS AND USAGE</a>,</span> and <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span> (total dosage regimen: 30 mg/kg, see <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>): Safety and effectiveness in the treatment of pediatric patients with <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> under 6 months of age have not been established.</p>
<p>Acute Bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> (dosage regimen: 10 mg/kg on Days 1–3): Safety and effectiveness in the treatment of pediatric patients with acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> under 6 months of age have not been established. Use of Zithromax for the treatment of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> in pediatric patients (6 months of age or greater) is supported by adequate and well-controlled studies in adults, similar pathophysiology of <span class="product-label-link" type="condition" conceptid="260123" conceptname="Acute sinusitis">acute sinusitis</span> in adults and pediatric patients, and studies of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> in pediatric patients. </p>
<p>Community-Acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> (dosage regimen: 10 mg/kg on Day 1 followed by 5 mg/kg on Days 2–5): Safety and effectiveness in the treatment of pediatric patients with community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> under 6 months of age have not been established. Safety and effectiveness for <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to <span class="Italics">Chlamydia pneumoniae</span> and <span class="Italics">Mycoplasma pneumoniae</span> were documented in pediatric clinical trials. Safety and effectiveness for <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> due to <span class="Italics">Haemophilus influenzae </span>and <span class="Italics">Streptococcus pneumoniae </span>were not documented bacteriologically in the pediatric clinical trial due to difficulty in obtaining specimens. Use of azithromycin for these two microorganisms is supported, however, by evidence from adequate and well-controlled studies in adults.</p>
<p><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> (dosage regimen: 12 mg/kg on Days 1–5): Safety and effectiveness in the treatment of pediatric patients with <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> under 2 years of age have not been established.</p>
<p><span class="Bold">Studies evaluating the use of repeated courses of therapy have not been conducted. (</span>See <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a> and <a href="#ANIMAL">ANIMAL TOXICOLOGY</a>.)</span></p>
<p>
 
</p>
<p></p>
<p>Pharmacokinetic parameters in older volunteers (65–85 years old) were similar to those in younger volunteers (18–40 years old) for the 5-day therapeutic regimen. Dosage adjustment does not appear to be necessary for older patients with normal renal and hepatic function receiving treatment with this dosage regimen. (See <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span>.)</p>
<p>In multiple-dose clinical trials of oral azithromycin, 9% of patients were at least 65 years of age (458/4949) and 3% of patients (144/4949) were at least 75 years of age. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in response between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
<p>ZITHROMAX 250 mg tablets contain 0.9 mg of sodium per tablet.</p>
<p>ZITHROMAX 500 mg tablets contain 1.8 mg of sodium per tablet.</p>
<p>ZITHROMAX for oral suspension 100 mg/5 mL contains 3.7 mg of sodium per 5 mL of constituted solution.</p>
<p>ZITHROMAX for oral suspension 200 mg/5 mL contains 7.4 mg of sodium per 5 mL of constituted solution.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>In clinical trials, most of the reported side effects were mild to moderate in severity and were reversible upon discontinuation of the drug. Potentially serious side effects of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> were reported rarely. Approximately 0.7% of the patients (adults and pediatric patients) from the 5-day multiple-dose clinical trials discontinued ZITHROMAX (azithromycin) therapy because of treatment-related side effects. In adults given 500 mg/day for 3 days, the discontinuation rate due to treatment-related side effects was 0.6%. In clinical trials in pediatric patients given 30 mg/kg, either as a single dose or over 3 days, discontinuation from the trials due to treatment-related side effects was approximately 1%. (See <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>.) Most of the side effects leading to discontinuation were related to the gastrointestinal tract, e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>. (See <span class="Bold"><a href="#CS_pediatric">CLINICAL STUDIES IN PEDIATRIC PATIENTS</a></span>.)</p>
<p>
 
</p>
<p></p>
<p>Overall, the most common treatment-related side effects in adult patients receiving multiple-dose regimens of ZITHROMAX were related to the gastrointestinal system with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (4–5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%) and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2–3%) being the most frequently reported.</p>
<p>No other treatment-related side effects occurred in patients on the multiple-dose regimens of ZITHROMAX with a frequency greater than 1%. Side effects that occurred with a frequency of 1% or less included the following:</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span> and <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>.</p>
<p><span class="Bold">Genitourinary:</span> Monilia, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> and <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>.</p>
<p><span class="Bold">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span>.</p>
<p><span class="Bold">Allergic:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p>
 
</p>
<p></p>
<p>Overall, the most common side effects in patients receiving a single-dose regimen of 1 gram of ZITHROMAX were related to the gastrointestinal system and were more frequently reported than in patients receiving the multiple-dose regimen.</p>
<p>Side effects that occurred in patients on the single one-gram dosing regimen of ZITHROMAX with a frequency of 1% or greater included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (7%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (5%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (1%) and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (1%).</p>
<p>
 
</p>
<p></p>
<p>Overall, the most common side effects in patients receiving a single 2-gram dose of ZITHROMAX were related to the gastrointestinal system. Side effects that occurred in patients in this study with a frequency of 1% or greater included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (18%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (14%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (7%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (7%), <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> (2%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (1%) and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (1%). The majority of these complaints were mild in nature.</p>
<p>
 
</p>
<p></p>
<p>The types of side effects in pediatric patients were comparable to those seen in adults, with different incidence rates for the dosage regimens recommended in pediatric patients.</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis Media</span>: For the recommended total dosage regimen of 30 mg/kg, the most frequent side effects (≥1%) attributed to treatment were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. (See <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span> and <span class="Bold"><a href="#CS_pediatric">CLINICAL STUDIES IN PEDIATRIC PATIENTS</a></span>.) </p>
<p>The incidence, based on dosing regimen, is described in the table below:</p>
<table width="75%">
<col align="left" span="1" width="17%">
<col align="center" span="1" width="17%">
<col align="center" span="1" width="17%">
<col align="center" span="1" width="17%">
<col align="center" span="1" width="16%">
<col align="center" span="1" width="16%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Dosage<br>Regimen</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, %</th>
<th align="center" colspan="1">Abdominal<br> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, %</th>
</tr>
<tr>
<td align="left">1-day</td>
<td align="center">4.3%</td>
<td align="center">1.4%</td>
<td align="center">4.9%</td>
<td align="center">1.0%</td>
<td align="center">1.0%</td>
</tr>
<tr>
<td align="left">3-day</td>
<td align="center">2.6%</td>
<td align="center">1.7%</td>
<td align="center">2.3%</td>
<td align="center">0.4%</td>
<td align="center">0.6%</td>
</tr>
<tr class="Last">
<td align="left">5-day</td>
<td align="center">1.8%</td>
<td align="center">1.2%</td>
<td align="center">1.1%</td>
<td align="center">0.5%</td>
<td align="center">0.4%</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p>For the recommended dosage regimen of 10 mg/kg on Day 1 followed by 5 mg/kg on Days 2–5, the most frequent side effects attributed to treatment were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>The incidence is described in the table below:</p>
<table width="85%">
<col align="left" span="1" width="17%">
<col align="center" span="1" width="17%">
<col align="center" span="1" width="17%">
<col align="center" span="1" width="17%">
<col align="center" span="1" width="16%">
<col align="center" span="1" width="16%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Dosage<br>Regimen</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span>, %</th>
<th align="center" colspan="1">Abdominal<br><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, %</th>
</tr>
<tr class="Last">
<td align="left">5-day</td>
<td align="center">5.8%</td>
<td align="center">1.9%</td>
<td align="center">1.9%</td>
<td align="center">1.9%</td>
<td align="center">1.6%</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p>For the recommended dosage regimen of 12 mg/kg on Days 1–5, the most frequent side effects attributed to treatment were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.</p>
<p>The incidence is described in the table below:</p>
<table width="95%">
<col align="left" span="1" width="17%">
<col align="center" span="1" width="17%">
<col align="center" span="1" width="17%">
<col align="center" span="1" width="17%">
<col align="center" span="1" width="16%">
<col align="center" span="1" width="16%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Dosage<br>Regimen</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, %</th>
<th align="center" colspan="1"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, %</th>
<th colspan="1"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, %</th>
</tr>
<tr class="Last">
<td align="left">5-day</td>
<td align="center">5.4%</td>
<td align="center">3.4%</td>
<td align="center">5.6%</td>
<td align="center">1.8%</td>
<td align="center">0.7%</td>
<td>1.1%</td>
</tr>
</tbody>
</table>
<p>With any of the treatment regimens, no other treatment-related side effects occurred in pediatric patients treated with ZITHROMAX with a frequency greater than 1%. Side effects that occurred with a frequency of 1% or less included the following:</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="201773" conceptname="Enteritis of small intestine">enteritis</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> and <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral moniliasis</span>.</p>
<p><span class="Bold">Hematologic and Lymphatic:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>.</p>
<p><span class="Bold">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> (<span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> dosage), <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p><span class="Bold">Allergic:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p><span class="Bold">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusion</span> and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>.</p>
<p><span class="Bold">Skin and Appendages:</span> <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span>, <span class="product-label-link" type="condition" conceptid="137213" conceptname="Dermal mycosis">fungal dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>.</p>
<p><span class="Bold">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>.</p>
<p>
 
</p>
<p></p>
<p>Adverse events reported with azithromycin during the post-marketing period in adult and/or pediatric patients for which a causal relationship may not be established include:</p>
<p><span class="Bold">Allergic:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
<p><span class="Bold">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmias</span> including <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. There have been rare reports of QT prolongation and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span></span>.</p>
<p><span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> rarely resulting in <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">oral candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4273754" conceptname="Pyloric stenosis">pyloric stenosis</span>, and rare reports of <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">tongue discoloration</span>.</p>
<p><span class="Bold">General:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> (rarely fatal).</p>
<p><span class="Bold">Genitourinary:</span> Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>.</p>
<p><span class="Bold">Hematopoietic:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>.</p>
<p><span class="Bold">Liver/Biliary:</span> Adverse reactions related to hepatic dysfunction have been reported in postmarketing experience with azithromycin. (See <span class="Bold"><a href="#hepa">WARNINGS, Hepatotoxicity</a></span>.)</p>
<p><span class="Bold">Nervous System:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.</p>
<p><span class="Bold">Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive reaction</span> and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>.</p>
<p><span class="Bold">Skin/Appendages:</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, rarely serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens Johnson Syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>.</p>
<p><span class="Bold">Special Senses:</span> Hearing disturbances including <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span> and/or <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and reports of taste/<span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">smell perversion</span> and/or loss.</p>
<p>
 
</p>
<p></p>
<p>Clinically significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows: with an incidence of greater than 1%: <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">decreased hemoglobin</span>, hematocrit, <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and blood glucose; elevated serum creatine phosphokinase, potassium, ALT, GGT, AST, BUN, creatinine, blood glucose, platelet count, <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and eosinophils; with an incidence of less than 1%: <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, decreased sodium, potassium, platelet count, elevated monocytes, <span class="product-label-link" type="condition" conceptid="4172647" conceptname="Basophil count">basophils</span>, <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, serum alkaline phosphatase, bilirubin, LDH and phosphate. The majority of subjects with elevated serum creatinine also had abnormal values at baseline.</p>
<p>When follow-up was provided, changes in laboratory tests appeared to be reversible.</p>
<p>In multiple-dose clinical trials involving more than 5000 patients, four patients discontinued therapy because of treatment-related liver enzyme abnormalities and one because of a renal function abnormality.</p>
<p>
 
</p>
<p></p>
<p>Laboratory data collected from comparative clinical trials employing two 3-day regimens (30 mg/kg or 60 mg/kg in divided doses over 3 days), or two 5-day regimens (30 mg/kg or 60 mg/kg in divided doses over 5 days) were similar for regimens of azithromycin and all comparators combined, with most clinically significant laboratory abnormalities occurring at incidences of 1–5%. Laboratory data for patients receiving 30 mg/kg as a single dose were collected in one single center trial. In that trial, an absolute neutrophil count between 500–1500 cells/mm<span class="Sup">3</span> was observed in 10/64 patients receiving 30 mg/kg as a single dose, 9/62 patients receiving 30 mg/kg given over 3 days, and 8/63 comparator patients. No patient had an absolute neutrophil count &lt;500 cells/mm<span class="Sup">3</span>. (See <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span>.<span class="Bold">)</span></p>
<p>In multiple-dose clinical trials involving approximately 4700 pediatric patients, no patients discontinued therapy because of treatment-related laboratory abnormalities.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p><span class="Bold">(</span>See <span class="Bold"><a href="#INDICATIONS">INDICATIONS AND USAGE</a></span> and <span class="Bold"><a href="#CLINICAL">CLINICAL PHARMACOLOGY</a></span>.<span class="Bold">)</span></p>
<p>
 
</p>
<p></p>
<table width="100%">
<col align="left" span="1" valign="top" width="50%">
<col align="left" span="1" valign="top" width="50%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span><a href="#footnote-1">*</a>
</th>
<th align="left" colspan="1">Recommended Dose/Duration of Therapy</th>
</tr>
<tr>
<td align="left">Community-aquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (mild severity)<br> <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> (second line therapy)<br> Skin/skin structure (uncomplicated)</td>
<td align="left">500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.</td>
</tr>
<tr>
<td align="left">Acute bacterial exacerbations of chronic<br> obstructive pulmonary disease (mild to moderate)</td>
<td align="left">500 mg QD × 3 days<br> OR<br> 500 mg as a single dose on Day 1, followed by 250 mg once daily on Days 2 through 5.</td>
</tr>
<tr>
<td align="left">Acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span></td>
<td align="left">500 mg QD × 3 days</td>
</tr>
<tr>
<td align="left">Genital <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease (<span class="product-label-link" type="condition" conceptid="138973" conceptname="Chancroid">chancroid</span>)</td>
<td align="left">One single 1 gram dose</td>
</tr>
<tr>
<td align="left">Non-gonoccocal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> and <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span></td>
<td align="left">One single 1 gram dose</td>
</tr>
<tr>
<td align="left">Gonococcal <span class="product-label-link" type="condition" conceptid="195862" conceptname="Urethritis">urethritis</span> and <span class="product-label-link" type="condition" conceptid="196163" conceptname="Cervicitis and endocervicitis">cervicitis</span></td>
<td align="left">One single 2 gram dose</td>
</tr>
<tr class="Last"><td align="left"></td></tr>
</tbody>
</table>
<p><a name="footnote-reference-12" href="#footnote-12" class="Sup">12</a></p>
<p>ZITHROMAX tablets can be taken with or without food.</p>
<p>
 
</p>
<p></p>
<p>No dosage adjustment is recommended for subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR ≤80 mL/min). The mean AUC<span class="Sub">0–120</span> was similar in subjects with GFR 10–80 mL/min compared to subjects with normal renal function, whereas it increased 35% in subjects with GFR &lt;10 mL/min compared to subjects with normal renal function. Caution should be exercised when azithromycin is administered to subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. (See <span class="Bold"><a href="#renal">CLINICAL PHARMACOLOGY, Special Populations, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></a>.</span>)</p>
<p>
 
</p>
<p></p>
<p>The pharmacokinetics of azithromycin in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been established. No dose adjustment recommendations can be made in patients with impaired hepatic function (See <span class="Bold"><a href="#hepatic">CLINICAL PHARMACOLOGY, Special Populations, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span>.</a></span>)</p>
<p>
 
</p>
<p></p>
<p>No dosage adjustment is recommended based on age or gender. (See <span class="Bold"><a href="#special">CLINICAL PHARMACOLOGY, Special Populations</a>.</span>)</p>
<p>
 
</p>
<p></p>
<p>ZITHROMAX for oral suspension can be taken with or without food.</p>
<p>
 
</p>
<p></p>
<p>The recommended dose of ZITHROMAX for oral suspension for the treatment of pediatric patients with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> is 30 mg/kg given as a single dose or 10 mg/kg once daily for 3 days or 10 mg/kg as a single dose on the first day followed by 5 mg/kg/day on Days 2 through 5. (See chart below.)</p>
<p>
 
</p>
<p></p>
<p>The recommended dose of ZITHROMAX for oral suspension for the treatment of pediatric patients with acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> is 10 mg/kg once daily for 3 days. (See chart below.)</p>
<p>
 
</p>
<p></p>
<p>The recommended dose of ZITHROMAX for oral suspension for the treatment of pediatric patients with community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> is 10 mg/kg as a single dose on the first day followed by 5 mg/kg on Days 2 through 5. (See chart below.)</p>
<p>PEDIATRIC DOSAGE GUIDELINES FOR <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span>, ACUTE BACTERIAL <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">SINUSITIS</span> AND 	COMMUNITY-ACQUIRED <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">PNEUMONIA</span> (Age 6 months and above, see <a href="#P_pediatric">PRECAUTIONS—Pediatric Use</a>.) Based on Body Weight</p>
<table width="100%">
<col align="left" span="1" valign="top" width="5%">
<col align="left" span="1" valign="top" width="5%">
<col align="center" span="1" valign="top" width="10%">
<col align="center" span="1" valign="top" width="10%">
<col align="center" span="1" valign="top" width="10%">
<col align="center" span="1" valign="top" width="10%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="8"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span> AND COMMUNITY-ACQUIRED <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">PNEUMONIA</span>: (5-Day Regimen)<a href="#footnote-1">*</a>
</th></tr>
<tr><th align="left" colspan="8">Dosing Calculated on 10 mg/kg/day Day 1 and 5 mg/kg/day Days 2 to 5.</th></tr>
<tr>
<th align="left" colspan="2">Weight</th>
<th align="center" colspan="2">100 mg/5 mL</th>
<th align="center" colspan="2"> 200 mg/5 mL</th>
<th align="center" colspan="1">Total mL per Treatment Course</th>
<th align="center" colspan="1">Total mg per Treatment Course</th>
</tr>
<tr>
<th align="left" colspan="1">Kg</th>
<th align="left" colspan="1">Lbs.</th>
<th align="center" colspan="1">Day 1</th>
<th align="center" colspan="1">Days 2–5</th>
<th align="center" colspan="1">Day 1</th>
<th align="center" colspan="1">Days 2–5</th>
</tr>
<tr><th align="left" colspan="8"></th></tr>
<tr>
<td align="left">5</td>
<td align="left">11</td>
<td align="center">2.5 mL<br> (½ tsp)</td>
<td align="center">1.25 mL<br> (¼ tsp)</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">7.5 mL</td>
<td align="center">150 mg</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">22</td>
<td align="center">5 mL<br>(1 tsp)</td>
<td align="center">2.5 mL<br>(½ tsp)</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">15 mL</td>
<td align="center">300 mg</td>
</tr>
<tr>
<td align="left">20</td>
<td align="left">44</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">5 mL<br>(1 tsp)</td>
<td align="center">2.5 mL<br>(½ tsp)</td>
<td align="center">15 mL</td>
<td align="center">600 mg</td>
</tr>
<tr>
<td align="left">30</td>
<td align="left">66</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">7.5 mL<br>(1½ tsp)</td>
<td align="center">3.75 mL<br>(¾ tsp)</td>
<td align="center">22.5 mL</td>
<td align="center">900 mg</td>
</tr>
<tr>
<td align="left">40</td>
<td align="left">88</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">10 mL<br>(2 tsp)</td>
<td align="center">5 mL<br>(1 tsp)</td>
<td align="center">30 mL</td>
<td align="center">1200 mg</td>
</tr>
<tr class="Last">
<td align="left">50 and above</td>
<td align="left">110 and above</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">12.5 mL<br> (2½ tsp)</td>
<td align="center">6.25 mL<br> (1¼ tsp)</td>
<td align="center">37.5 mL</td>
<td align="center">1500 mg</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-13" href="#footnote-13" class="Sup">13</a></p>
<table width="90%">
<col align="left" span="1" valign="top" width="10%">
<col align="left" span="1" valign="top" width="10%">
<col align="center" span="1" valign="top" width="15%">
<col align="center" span="1" valign="top" width="15%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="6"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span> AND ACUTE BACTERIAL <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">SINUSITIS</span>: (3-Day Regimen)<a href="#footnote-2">*</a>
</th></tr>
<tr><th align="left" colspan="6">Dosing Calculated on 10 mg/kg/day</th></tr>
<tr>
<th align="left" colspan="2">Weight</th>
<th align="center" colspan="1">100 mg/5 mL</th>
<th align="center" colspan="1"> 200 mg/5 mL</th>
<th align="center" colspan="1">Total mL per Treatment Course</th>
<th align="center" colspan="1">Total mg per Treatment Course</th>
</tr>
<tr>
<th align="left" colspan="1">Kg</th>
<th align="left" colspan="1">Lbs.</th>
<th align="center" colspan="1">Day 1–3</th>
<th align="center" colspan="1">Day 1–3</th>
</tr>
<tr><th align="left" colspan="6"></th></tr>
<tr>
<td align="left">5</td>
<td align="left">11</td>
<td align="center">2.5 mL<br> (1/2 tsp)</td>
<td align="center"></td>
<td align="center">7.5 mL</td>
<td align="center">150 mg</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">22</td>
<td align="center">5 mL<br> (1 tsp)</td>
<td align="center"></td>
<td align="center">15 mL</td>
<td align="center">300 mg</td>
</tr>
<tr>
<td align="left">20</td>
<td align="left">44</td>
<td align="center"></td>
<td align="center">5 mL<br> (1 tsp)</td>
<td align="center">15 mL</td>
<td align="center">600 mg</td>
</tr>
<tr>
<td align="left">30</td>
<td align="left">66</td>
<td align="center"></td>
<td align="center">7.5 mL<br> (1 ½ tsp)</td>
<td align="center">22.5 mL</td>
<td align="center">900 mg</td>
</tr>
<tr>
<td align="left">40</td>
<td align="left">88</td>
<td align="center"></td>
<td align="center">10 mL<br> (2 tsp)</td>
<td align="center">30 mL</td>
<td align="center">1200 mg</td>
</tr>
<tr class="Last">
<td align="left">50 and above</td>
<td align="left">110 and above</td>
<td align="center"></td>
<td align="center">12.5 mL<br> (2 ½ tsp)</td>
<td align="center">37.5 mL</td>
<td align="center">1500 mg</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-14" href="#footnote-14" class="Sup">14</a></p>
<table width="90%">
<col align="left" span="1" valign="top" width="12%">
<col align="left" span="1" valign="top" width="13%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="5"><span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">OTITIS MEDIA</span>: (1-Day Regimen)</th></tr>
<tr><th align="left" colspan="5">Dosing Calculated on 30 mg/kg as a single dose</th></tr>
<tr>
<th align="left" colspan="2">Weight</th>
<th align="center" colspan="1"> 200 mg/5 mL</th>
<th align="center" colspan="1">Total mL per Treatment Course</th>
<th align="center" colspan="1">Total mg per Treatment Course</th>
</tr>
<tr>
<th align="left" colspan="1">Kg</th>
<th align="left" colspan="1">Lbs.</th>
<th align="center" colspan="1">Day 1</th>
</tr>
<tr><th align="left" colspan="5"></th></tr>
<tr>
<td align="left">5</td>
<td align="left">11</td>
<td align="center">3.75 mL<br> (3/4 tsp)</td>
<td align="center">3.75 mL<br>
</td>
<td align="center">150 mg</td>
</tr>
<tr>
<td align="left">10</td>
<td align="left">22</td>
<td align="center">7.5 mL<br> (1 ½ tsp)</td>
<td align="center">7.5 mL</td>
<td align="center">300 mg</td>
</tr>
<tr>
<td align="left">20</td>
<td align="left">44</td>
<td align="center">15 mL<br> (3 tsp)</td>
<td align="center">15 mL</td>
<td align="center">600 mg</td>
</tr>
<tr>
<td align="left">30</td>
<td align="left">66</td>
<td align="center">22.5 mL<br> (4 ½ tsp)</td>
<td align="center">22.5 mL</td>
<td align="center">900 mg</td>
</tr>
<tr>
<td align="left">40</td>
<td align="left">88</td>
<td align="center">30 mL<br> (6 tsp)</td>
<td align="center">30 mL</td>
<td align="center">1200 mg</td>
</tr>
<tr class="Last">
<td align="left">50 and above</td>
<td align="left">110 and above</td>
<td align="center">37.5 mL<br> (7 ½ tsp)</td>
<td align="center">37.5 mL</td>
<td align="center">1500 mg</td>
</tr>
</tbody>
</table>
<p>The safety of re-dosing azithromycin in pediatric patients who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> given a single 30 mg/kg dose of azithromycin, eight patients who <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomited</span> within 30 minutes of dosing were re-dosed at the same total dose.</p>
<p>
 
</p>
<p></p>
<p>The recommended dose of ZITHROMAX for children with <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> is 12 mg/kg once daily for 5 days. (See chart below.)</p>
<p>PEDIATRIC DOSAGE GUIDELINES FOR <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">PHARYNGITIS</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">TONSILLITIS</span> (Age 2 years and above, see <a href="#P_pediatric">PRECAUTIONS—Pediatric Use</a>.) Based on Body Weight</p>
<table width="100%">
<col align="left" span="1" valign="top" width="12%">
<col align="left" span="1" valign="top" width="13%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="5"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">PHARYNGITIS</span>/<span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">TONSILLITIS</span>: (5-Day Regimen)</th></tr>
<tr><th align="left" colspan="5">Dosing Calculated on 12 mg/kg/day for 5 days.</th></tr>
<tr>
<th align="left" colspan="2">Weight</th>
<th align="center" colspan="1"> 200 mg/5 mL</th>
<th align="center" colspan="1">Total mL per Treatment Course</th>
<th align="center" colspan="1">Total mg per Treatment Course</th>
</tr>
<tr>
<th align="left" colspan="1">Kg</th>
<th align="left" colspan="1">Lbs.</th>
<th align="center" colspan="1">Day 1–5</th>
</tr>
<tr><th align="left" colspan="5"></th></tr>
<tr>
<td align="left">8</td>
<td align="left">18</td>
<td align="center">2.5 mL<br>(½ tsp)</td>
<td align="center">12.5 mL</td>
<td align="center">500 mg</td>
</tr>
<tr>
<td align="left">17</td>
<td align="left">37</td>
<td align="center">5 mL<br>(1 tsp)</td>
<td align="center">25 mL</td>
<td align="center">1000 mg</td>
</tr>
<tr>
<td align="left">25</td>
<td align="left">55</td>
<td align="center">7.5 mL<br>(1½ tsp)</td>
<td align="center">37.5 mL</td>
<td align="center">1500 mg</td>
</tr>
<tr>
<td align="left">33</td>
<td align="left">73</td>
<td align="center">10 mL<br>(2 tsp)</td>
<td align="center">50 mL</td>
<td align="center">2000 mg</td>
</tr>
<tr class="Last">
<td align="left">40</td>
<td align="left">88</td>
<td align="center">12.5 mL<br>(2½ tsp)</td>
<td align="center">62.5 mL</td>
<td align="center">2500 mg</td>
</tr>
</tbody>
</table>
<p>Constituting instructions for ZITHROMAX Oral Suspension, 300, 600, 900, 1200 mg bottles. The table below indicates the volume of water to be used for constitution:</p>
<table width="75%">
<col align="left" span="1" width="33%">
<col align="left" span="1" width="34%">
<col align="left" span="1" width="33%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Amount of water to be added</th>
<th align="left" colspan="1">Total volume after constitution (azithromycin content)</th>
<th align="left" colspan="1">Azithromycin concentration after constitution</th>
</tr>
<tr>
<td align="left">9 mL (300 mg)</td>
<td align="left">15 mL (300 mg)</td>
<td align="left">100 mg/5 mL</td>
</tr>
<tr>
<td align="left">9 mL (600 mg)</td>
<td align="left">15 mL (600 mg)</td>
<td align="left">200 mg/5 mL</td>
</tr>
<tr>
<td align="left">12 mL (900 mg)</td>
<td align="left">22.5 mL (900 mg)</td>
<td align="left">200 mg/5 mL</td>
</tr>
<tr class="Last">
<td align="left">15 mL (1200 mg)</td>
<td align="left">30 mL (1200 mg)</td>
<td align="left">200 mg/5 mL</td>
</tr>
</tbody>
</table>
<p>Shake well before each use. Oversized bottle provides shake space. Keep tightly closed.</p>
<p>After mixing, store suspension at 5° to 30°C (41° to 86°F) and use within 10 days. Discard after full dosing is completed.</p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">12</a></dt>
<dd>See </dd>
<dt><a name="footnote-13" href="#footnote-reference-13">13</a></dt>
<dd>Effectiveness of the 3-day or 1-day regimen in pediatric patients with community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> has not been established.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">14</a></dt>
<dd>Effectiveness of the 5-day or 1-day regimen in pediatric patients with acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span> has not been established.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>ZITHROMAX 250 mg tablets are supplied as pink modified capsular shaped, engraved, film-coated tablets containing azithromycin dihydrate equivalent to 250 mg of azithromycin. ZITHROMAX 250 mg tablets are engraved with "PFIZER" on one side and "306" on the other. These are packaged in bottles and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 6 tablets (Z-PAKS<span class="Sup">®</span>) as follows:</p>
<table width="65%">
<col align="left" span="1" width="40%">
<col align="left" span="1" width="60%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
</tr>
<tr>
<td align="left">Bottles of 30</td>
<td align="left">NDC 0069-3060-30</td>
</tr>
<tr>
<td align="left">Boxes of 3 (Z-PAKS<span class="Sup">®</span> of 6)</td>
<td align="left">NDC 0069-3060-75</td>
</tr>
<tr class="Last">
<td align="left">Unit Dose package of 50</td>
<td align="left">NDC 0069-3060-86</td>
</tr>
</tbody>
</table>
<p>ZITHROMAX 500 mg tablets are supplied as pink modified capsular shaped, engraved, film-coated tablets containing azithromycin dihydrate equivalent to 500 mg of azithromycin. ZITHROMAX 500 mg tablets are engraved with "Pfizer" on one side and "ZTM500" on the other. These are packaged in bottles and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards of 3 tablets (TRI-PAKS™) as follows:</p>
<table width="75%">
<col align="left" span="1" width="40%">
<col align="left" span="1" width="60%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
</tr>
<tr>
<td align="left">Bottles of 30</td>
<td align="left">NDC 0069-3070-30</td>
</tr>
<tr>
<td align="left">Boxes of 3 (TRI-PAKS™ of 3 tablets)</td>
<td align="left">NDC 0069-3070-75</td>
</tr>
<tr class="Last">
<td align="left">Unit Dose package of 50</td>
<td align="left">NDC 0069-3070-86</td>
</tr>
</tbody>
</table>
<p>ZITHROMAX tablets should be stored between 15° to 30°C (59° to 86°F).</p>
<p>ZITHROMAX for oral suspension after constitution contains a flavored suspension. ZITHROMAX<span class="Sup">®</span> for oral suspension is supplied to provide 100 mg/5 mL or 200 mg/5 mL suspension in bottles as follows:</p>
<table width="75%">
<col align="center" span="1" width="75%">
<col align="center" span="1" width="25%">
<tbody class="Headless">
<tr class="First">
<th align="center" colspan="1"><span class="Underline">Azithromycin contents per bottle</span></th>
<th align="center" colspan="1">NDC</th>
</tr>
<tr>
<td align="center">300 mg</td>
<td align="center">0069-3110-19</td>
</tr>
<tr>
<td align="center">600 mg</td>
<td align="center">0069-3120-19</td>
</tr>
<tr>
<td align="center">900 mg</td>
<td align="center">0069-3130-19</td>
</tr>
<tr class="Last">
<td align="center">1200 mg</td>
<td align="center">0069-3140-19</td>
</tr>
</tbody>
</table>
<p>See <span class="Bold"><a href="#DOSAGE">DOSAGE AND ADMINISTRATION</a></span> for constitution instructions with each bottle type.</p>
<p>
 
</p>
<p></p>
<p>Store dry powder below 30°C (86°F). Store constituted suspension between 5° to 30°C (41° to 86°F) and discard when full dosing is completed.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-11"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p>(See <span class="Bold"><a href="#INDICATIONS">INDICATIONS AND USAGE</a></span> and <span class="Bold"><a href="#P_pediatric">Pediatric Use</a></span>.<span class="Bold">)</span></p>
<p>
 
</p>
<p></p>
<p>From the perspective of evaluating pediatric clinical trials, Days 11–14 were considered on-therapy evaluations because of the extended half-life of azithromycin. Day 11–14 data are provided for clinical guidance. Day 24–32 evaluations were considered the primary test of cure endpoint.</p>
<p>
 
</p>
<p></p>
<p>In a double-blind, controlled clinical study of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> performed in the United States, azithromycin (10 mg/kg on Day 1 followed by 5 mg/kg on Days 2–5) was compared to amoxicillin/clavulanate potassium (4:1). For the 553 patients who were evaluated for clinical efficacy, the clinical success rate (i.e., cure plus improvement) at the Day 11 visit was 88% for azithromycin and 88% for the control agent. For the 521 patients who were evaluated at the Day 30 visit, the clinical success rate was 73% for azithromycin and 71% for the control agent.</p>
<p>In the safety analysis of the above study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 9% with azithromycin and 31% with the control agent. The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (4% azithromycin vs. 20% control), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2% azithromycin vs. 7% control), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (2% azithromycin vs. 5% control).</p>
<p>
 
</p>
<p></p>
<p>In a non-comparative clinical and microbiologic trial performed in the United States, where significant rates of beta-lactamase producing organisms (35%) were found, 131 patients were evaluable for clinical efficacy. The combined clinical success rate (i.e., cure and improvement) at the Day 11 visit was 84% for azithromycin. For the 122 patients who were evaluated at the Day 30 visit, the clinical success rate was 70% for azithromycin.</p>
<p>Microbiologic determinations were made at the pre-treatment visit. Microbiology was not reassessed at later visits. The following presumptive bacterial/clinical cure outcomes (i.e., clinical success) were obtained from the evaluable group:</p>
<table width="75%">
<col align="left" span="1" width="32%">
<col align="left" span="1" width="34%">
<col align="left" span="1" width="34%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="3">Presumed Bacteriologic Eradication</th></tr>
<tr>
<th align="left" colspan="1"></th>
<th align="left" colspan="1">Day 11</th>
<th align="left" colspan="1">Day 30</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="left" colspan="1">Azithromycin</th>
<th align="left" colspan="1">Azithromycin</th>
</tr>
<tr>
<td align="left"><span class="Italics">S. pneumoniae</span></td>
<td align="left">61/74 (82%)</td>
<td align="left">40/56 (71%)</td>
</tr>
<tr>
<td align="left"><span class="Italics">H. influenzae</span></td>
<td align="left">43/54 (80%)</td>
<td align="left">30/47 (64%)</td>
</tr>
<tr>
<td align="left"><span class="Italics">M. catarrhalis</span></td>
<td align="left">28/35 (80%)</td>
<td align="left">19/26 (73%)</td>
</tr>
<tr>
<td align="left"><span class="Italics">S. pyogenes</span></td>
<td align="left">11/11 (100%)</td>
<td align="left">7/7</td>
</tr>
<tr class="Last">
<td align="left">Overall</td>
<td align="left">177/217 (82%)</td>
<td align="left">97/137 (73%)</td>
</tr>
</tbody>
</table>
<p>In the safety analysis of this study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 9%. The most common side effect was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (4%).</p>
<p>
 
</p>
<p></p>
<p>In another controlled comparative clinical and microbiologic study of <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> performed in the United States, azithromycin was compared to amoxicillin/clavulanate potassium (4:1). This study utilized two of the same investigators as Protocol 2 (above), and these two investigators enrolled 90% of the patients in Protocol 3. For this reason, Protocol 3 was not considered to be an independent study. Significant rates of beta-lactamase producing organisms (20%) were found. Ninety-two (92) patients were evaluable for clinical and microbiologic efficacy. The combined clinical success rate (i.e., cure and improvement) of those patients with a baseline pathogen at the Day 11 visit was 88% for azithromycin vs. 100% for control; at the Day 30 visit, the clinical success rate was 82% for azithromycin vs. 80% for control.</p>
<p>Microbiologic determinations were made at the pre-treatment visit. Microbiology was not reassessed at later visits. At the Day 11 and Day 30 visits, the following presumptive bacterial/clinical cure outcomes (i.e., clinical success) were obtained from the evaluable group:</p>
<table width="75%">
<col align="left" span="1" width="20%">
<col align="left" span="1" width="20%">
<col align="left" span="1" width="20%">
<col align="left" span="1" width="20%">
<col align="left" span="1" width="20%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="5">Presumed Bacteriologic Eradication</th></tr>
<tr>
<th align="left" colspan="1"></th>
<th align="left" colspan="2">Day 11</th>
<th align="left" colspan="2">Day 30</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="left" colspan="1">Azithromycin</th>
<th align="left" colspan="1">Control</th>
<th align="left" colspan="1">Azithromycin</th>
<th align="left" colspan="1">Control</th>
</tr>
<tr>
<td align="left"><span class="Italics">S. pneumoniae</span></td>
<td align="left">25/29 (86%)</td>
<td align="left">26/26 (100%)</td>
<td align="left">22/28 (79%)</td>
<td align="left">18/22 (82%)</td>
</tr>
<tr>
<td align="left"><span class="Italics">H. influenzae</span></td>
<td align="left">9/11 (82%)</td>
<td align="left">9/9</td>
<td align="left">8/10 (80%)</td>
<td align="left">6/8</td>
</tr>
<tr>
<td align="left"><span class="Italics">M. catarrhalis</span></td>
<td align="left">7/7</td>
<td align="left">5/5</td>
<td align="left">5/5</td>
<td align="left">2/3</td>
</tr>
<tr>
<td align="left"><span class="Italics">S. pyogenes</span></td>
<td align="left">2/2</td>
<td align="left">5/5</td>
<td align="left">2/2</td>
<td align="left">4/4</td>
</tr>
<tr class="Last">
<td align="left">Overall</td>
<td align="left">43/49 (88%)</td>
<td align="left">45/45 (100%)</td>
<td align="left">37/45 (82%)</td>
<td align="left">30/37 (81%)</td>
</tr>
</tbody>
</table>
<p>In the safety analysis of the above study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 4% with azithromycin and 31% with the control agent. The most common side effect was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (2% azithromycin vs. 29% control).</p>
<p>
 
</p>
<p></p>
<p>In a double-blind, controlled, randomized clinical study of acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> in pediatric patients from 6 months to 12 years of age, azithromycin (10 mg/kg per day for 3 days) was compared to amoxicillin/clavulanate potassium (7:1) in divided doses q12h for 10 days. Each patient received active drug and placebo matched for the comparator.</p>
<p>For the 366 patients who were evaluated for clinical efficacy at the Day 12 visit, the clinical success rate (i.e., cure plus improvement) was 83% for azithromycin and 88% for the control agent. For the 362 patients who were evaluated at the Day 24–28 visit, the clinical success rate was 74% for azithromycin and 69% for the control agent.</p>
<p>In the safety analysis of the above study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 10.6% with azithromycin and 20.0% with the control agent. The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (5.9% azithromycin vs. 14.6% control), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2.1% azithromycin vs. 1.1% control), and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (0.0% azithromycin vs. 4.3% control).</p>
<p>
 
</p>
<p></p>
<p>A double blind, controlled, randomized trial was performed at nine clinical centers. Pediatric patients from 6 months to 12 years of age were randomized 1:1 to treatment with either azithromycin (given at 30 mg/kg as a single dose on Day 1) or amoxicillin/clavulanate potassium (7:1), divided q12h for 10 days. Each child received active drug, and placebo matched for the comparator.</p>
<p>Clinical response (Cure, Improvement, Failure) was evaluated at End of Therapy (Day 12–16) and Test of Cure (Day 28–32). Safety was evaluated throughout the trial for all treated subjects. For the 321 subjects who were evaluated at End of Treatment, the clinical success rate (cure plus improvement) was 87% for azithromycin, and 88% for the comparator. For the 305 subjects who were evaluated at Test of Cure, the clinical success rate was 75% for both azithromycin and the comparator. </p>
<p>In the safety analysis, the incidence of treatment-related adverse events, primarily gastrointestinal, was 16.8% with azithromycin, and 22.5% with the comparator. The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6.4% with azithromycin vs. 12.7% with the comparator), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (4% with each agent), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1.7% with azithromycin vs. 5.2% with the comparator) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.7% with azithromycin vs. 1.2% with the comparator).</p>
<p>
 
</p>
<p></p>
<p>In a non-comparative clinical and microbiological trial, 248 patients from 6 months to 12 years of age with documented acute <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span> were dosed with a single oral dose of azithromycin (30 mg/kg on Day 1).</p>
<p>For the 240 patients who were evaluable for clinical modified Intent-to-Treat (MITT) analysis, the clinical success rate (i.e., cure plus improvement) at Day 10 was 89% and for the 242 patients evaluable at Day 24–28, the clinical success rate (cure) was 85%.</p>
<table width="75%">
<col align="left" span="1" width="32%">
<col align="left" span="1" width="34%">
<col align="left" span="1" width="34%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="3">Presumed Bacteriologic Eradication</th></tr>
<tr>
<th align="left" colspan="1"></th>
<th align="left" colspan="1">Day 10</th>
<th align="left" colspan="1">Day  24–28</th>
</tr>
<tr>
<td align="left"><span class="Italics">S. pneumoniae</span></td>
<td align="left">70/76 (92%)</td>
<td align="left">67/76 (88%)</td>
</tr>
<tr>
<td align="left"><span class="Italics">H. influenzae</span></td>
<td align="left">30/42 (71%)</td>
<td align="left">28/44 (64%)</td>
</tr>
<tr>
<td align="left"><span class="Italics">M. catarrhalis</span></td>
<td align="left">10/10 (100%)</td>
<td align="left">10/10 (100%)</td>
</tr>
<tr class="Last">
<td align="left">Overall</td>
<td align="left">110/128 (86%)</td>
<td align="left">105/130 (81%)</td>
</tr>
</tbody>
</table>
<p>In the safety analysis of this study, the incidence of treatment-related adverse events, primarily gastrointestinal, in all the subjects treated was 12.1%. The most common side effects were <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (5.6%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (3.2%), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (1.6%).</p>
<p>
 
</p>
<p></p>
<p>In three double-blind controlled studies, conducted in the United States, azithromycin (12 mg/kg once a day for 5 days) was compared to penicillin V (250 mg three times a day for 10 days) in the treatment of <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> due to documented Group A β-hemolytic streptococci (GABHS or <span class="Italics">S. pyogenes</span>). Azithromycin was clinically and microbiologically statistically superior to penicillin at Day 14 and Day 30 with the following clinical success (i.e., cure and improvement) and bacteriologic efficacy rates (for the combined evaluable patient with documented GABHS):</p>
<table width="75%">
<col align="left" span="1" width="40%">
<col align="center" span="1" width="30%">
<col align="center" span="1" width="30%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="3">Three U.S. <span class="product-label-link" type="condition" conceptid="28060" conceptname="Streptococcal sore throat">Streptococcal Pharyngitis</span> Studies</th></tr>
<tr><th align="left" colspan="3">Azithromycin vs. Penicillin V</th></tr>
<tr><th align="left" colspan="3">EFFICACY RESULTS</th></tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="1">Day 14</th>
<th align="center" colspan="1">Day 30</th>
</tr>
<tr><td align="left">Bacteriologic Eradication:</td></tr>
<tr>
<td align="left">  Azithromycin</td>
<td align="center">323/340 (95%)</td>
<td align="center">255/330 (77%)</td>
</tr>
<tr>
<td align="left">  Penicillin V</td>
<td align="center">242/332 (73%)</td>
<td align="center">206/325 (63%)</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">Clinical Success (Cure plus improvement):</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Azithromycin</td>
<td align="center">336/343 (98%)</td>
<td align="center">310/330 (94%)</td>
</tr>
<tr class="Last">
<td align="left">  Penicillin V</td>
<td align="center">284/338 (84%)</td>
<td align="center">241/325 (74%)</td>
</tr>
</tbody>
</table>
<p>Approximately 1% of azithromycin-susceptible <span class="Italics">S. pyogenes</span> isolates were resistant to azithromycin following therapy.</p>
<p>The incidence of treatment-related adverse events, primarily gastrointestinal, in all patients treated was 18% on azithromycin and 13% on penicillin. The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>/<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">loose stools</span> (6% azithromycin vs. 2% penicillin), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (6% azithromycin vs. 4% penicillin), and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (3% azithromycin vs. 1% penicillin).</p>
<p>
 
</p>
<p></p>
<p>In a randomized, double-blind controlled clinical trial of <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">acute exacerbation of chronic bronchitis</span> (AECB), azithromycin (500 mg once daily for 3 days) was compared with clarithromycin (500 mg twice daily for 10 days). The primary endpoint of this trial was the clinical cure rate at Day 21– 24. For the 304 patients analyzed in the modified intent to treat analysis at the Day 21–24 visit, the clinical cure rate for 3 days of azithromycin was 85% (125/147) compared to 82% (129/157) for 10 days of clarithromycin.</p>
<p>The following outcomes were the clinical cure rates at the Day 21–24 visit for the bacteriologically evaluable patients by pathogen:</p>
<table width="75%">
<col align="left" span="1" width="40 %">
<col align="center" span="1" width="30 %">
<col align="center" span="1" width="30 %">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Pathogen</th>
<th align="center" colspan="1">Azithromycin<br>(3 Days)</th>
<th align="center" colspan="1">Clarithromycin<br>(10 Days)</th>
</tr>
<tr>
<td align="left"><span class="Italics">S. pneumoniae</span></td>
<td align="center">29/32 (91%)</td>
<td align="center">21/27 (78%)</td>
</tr>
<tr>
<td align="left"><span class="Italics">H. influenzae</span></td>
<td align="center">12/14 (86%)</td>
<td align="center">14/16 (88%)</td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">M. catarrhalis</span></td>
<td align="center">11/12 (92%)</td>
<td align="center">12/15 (80%)</td>
</tr>
</tbody>
</table>
<p>In the safety analysis of this study, the incidence of treatment-related adverse events, primarily gastrointestinal, were comparable between treatment arms (25% with azithromycin and 29% with clarithromycin). The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> with comparable incidence rates for each symptom of 5–9% between the two treatment arms. (See <span class="Bold"><a href="#ADVERSE">ADVERSE REACTIONS</a>.</span>)</p>
<p>
 
</p>
<p></p>
<p>In a randomized, double blind, double-dummy controlled clinical trial of acute bacterial <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, azithromycin (500 mg once daily for 3 days) was compared with amoxicillin/clavulanate (500/125 mg tid for 10 days). Clinical response assessments were made at Day 10 and Day 28. The primary endpoint of this trial was prospectively defined as the clinical cure rate at Day 28. For the 594 patients analyzed in the modified intent to treat analysis at the Day 10 visit, the clinical cure rate for 3 days of azithromycin was 88% (268/303) compared to 85% (248/291) for 10 days of amoxicillin/clavulanate. For the 586 patients analyzed in the modified intent to treat analysis at the Day 28 visit, the clinical cure rate for 3 days of azithromycin was 71.5% (213/298) compared to 71.5% (206/288), with a 97.5% confidence interval of −8.4 to 8.3, for 10 days of amoxicillin/clavulanate.</p>
<p>In the safety analysis of this study, the overall incidence of treatment-related adverse events, primarily gastrointestinal, was lower in the azithromycin treatment arm (31%) than in the amoxicillin/clavulanate arm (51%). The most common side effects were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (17% in the azithromycin arm vs. 32% in the amoxicillin/clavulanate arm), and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (7% in the azithromycin arm vs. 12% in the amoxicillin/clavulanate arm). (See <span class="Bold"><a href="#ADVERSE">ADVERSE REACTIONS</a></span>).</p>
<p>In an open label, noncomparative study requiring baseline transantral sinus punctures the following outcomes were the clinical success rates at the Day 7 and Day 28 visits for the modified intent to treat patients administered 500 mg of azithromycin once daily for 3 days with the following pathogens:</p>
<table width="60%">
<col align="left" span="1" width="50%">
<col align="left" span="1" width="25%">
<col align="left" span="1" width="25%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Pathogen</th>
<th align="left" colspan="2">Azithromycin<br>(500 mg per day for 3 Days)</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="left" colspan="1"><span class="Italics">Day 7</span></th>
<th align="left" colspan="1"><span class="Italics">Day28</span></th>
</tr>
<tr>
<td align="left"><span class="Italics">S. pneumoniae</span></td>
<td align="left">23/26 (88%)</td>
<td align="left">21/25 (84%)</td>
</tr>
<tr>
<td align="left"><span class="Italics">H. influenzae</span></td>
<td align="left">28/32 (87%)</td>
<td align="left">24/32 (75%)</td>
</tr>
<tr class="Last">
<td align="left"><span class="Italics">M. catarrhalis</span></td>
<td align="left">14/15 (93%)</td>
<td align="left">13/15 (87%)</td>
</tr>
</tbody>
</table>
<p>The overall incidence of treatment-related adverse events in the noncomparative study was 21% in modified intent to treat patients treated with azithromycin at 500 mg once daily for 3 days with the most common side effects being <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (9%), <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (4%) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%). (See <span class="Bold"><a href="#ADVERSE">ADVERSE REACTIONS</a></span>).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="section-12"></a><p></p>
<h1>ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY</h1>
<p class="First"></p>
<p>Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats, and dogs given multiple doses of azithromycin. It has been demonstrated in numerous organ systems (e.g., eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and pancreas) in dogs treated with azithromycin at doses which, expressed on the basis of mg/m<span class="Sup">2</span>, are approximately equal to the recommended adult human dose, and in rats treated at doses approximately one-sixth of the recommended adult human dose. This effect has been shown to be reversible after cessation of azithromycin treatment. Phospholipidosis has been observed to a similar extent in the tissues of neonatal rats and dogs given daily doses of azithromycin ranging from 10 days to 30 days. Based on the pharmacokinetic data, phospholipidosis has been seen in the rat (30 mg/kg dose) at observed C<span class="Sub">max</span> value of 1.3 µg/mL (six times greater than the observed C<span class="Sub">max</span> of 0.216 µg/mL at the pediatric dose of 10 mg/kg). Similarly, it has been shown in the dog (10 mg/kg dose) at observed C<span class="Sub">max</span> value of 1.5 µg/mL (seven times greater than the observed same C<span class="Sub">max</span> and drug dose in the studied pediatric population). On a mg/m<span class="Sup">2</span> basis, 30 mg/kg dose in the neonatal rat (135 mg/m<span class="Sup">2</span>) and 10 mg/kg dose in the neonatal dog (79 mg/m<span class="Sup">2</span>) are approximately 0.5 and 0.3 times, respectively, the recommended dose in the pediatric patients with an average body weight of 25 kg. Phospholipidosis, similar to that seen in the adult animals, is reversible after cessation of azithromycin treatment. The significance of these findings for animals and for humans is unknown.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<ol>
<li>National Committee for Clinical Laboratory Standards<span class="Italics">, Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically</span> – Fifth Edition. Approved Standard NCCLS Document M7-A5, Vol. 20, No. 2 (ISBN 1-56238-394-9). NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898, January 2000. </li>
<li>National Committee for Clinical Laboratory Standards, <span class="Italics">Performance Standards for Antimicrobial Disk Susceptibility Tests</span> - Seventh Edition. Approved Standard NCCLS Document M2-A7, Vol. 20, No. 1 (ISBN 1-56238-393-0). NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898, January 2000.</li>
<li>National Committee for Clinical Laboratory Standards. <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing – </span>Eleventh Informational Supplement. NCCLS Document M100-S11, Vol. 21, No. 1 (ISBN 1-56238-426-0). NCCLS, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898, January 2001.</li>
</ol>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Bold">Rx only</span></p>
<p>Licensed from Pliva</p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=931a3c19-23d3-4b65-a422-32bd98de5de4&amp;name=MM2.jpg"></p>
<p>LAB-0023-10.0</p>
<p>January 2011</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Zithromax </p>
<p><br></p>
<p>GENERIC: azithromycin</p>
<p><br></p>
<p>DOSAGE: TABLET, FILM COATED</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 49349-743-10</p>
<p><br></p>
<p>STRENGTH:250 mg</p>
<p><br></p>
<p>COLOR: pink</p>
<p><br></p>
<p>SHAPE: OVAL</p>
<p><br></p>
<p>SCORE: No score</p>
<p><br></p>
<p>SIZE: 13 mm</p>
<p><br></p>
<p>IMPRINT: 6</p>
<p><br></p>
<p>QTY: 6</p>
<p><br></p>
<p><br></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=931a3c19-23d3-4b65-a422-32bd98de5de4&amp;name=MM3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ZITHROMAX 		
					</strong><br><span class="contentTableReg">azithromycin tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49349-743(NDC:0069-3060)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>AZITHROMYCIN, UNSPECIFIED FORM</strong> (AZITHROMYCIN ANHYDROUS) </td>
<td class="formItem">AZITHROMYCIN, UNSPECIFIED FORM</td>
<td class="formItem">250 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM LAURYL SULFATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (TABLET, FILM COATED) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PFIZER;306</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49349-743-10</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050711</td>
<td class="formItem">04/04/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fa3db135-ace4-4101-8f8e-960adff7fa01</div>
<div>Set id: 931a3c19-23d3-4b65-a422-32bd98de5de4</div>
<div>Version: 1</div>
<div>Effective Time: 20130404</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
